0

Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market by Product and Geography - Forecast and Analysis 2022-2026

  • Published: Apr 2022
  • Pages: 7
  • SKU: IRTNTR73132
Technavio

Enjoy complimentary customisation on priority with our Enterprise License!

Get me the latest version! (includes COVID-19 impact)
Safe and Secure SSL Encrypted

info
close
  • Single:

    One user only.
    Quick & easy download option

  • Enterprise:

    Unlimited user access (Within your organization)
    Complimentary Customization Included

2500 USD

The diffuse large B-cell lymphoma (DLBCL) therapeutics market share is expected to increase by USD 1.79 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 7.71%. The diffuse large b-cell lymphoma market report also offers information on several market vendors, including AbbVie Inc., ADC Therapeutics SA, Amgen Inc., Bayer AG, BeiGene Ltd., Bristol Myers Squibb Co., Celltrion Healthcare Co. Ltd., CTI BioPharma Corp., Denovo Biopharma, Erytech PharmaSA, F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Merck and Co. Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Seagen Inc., Spectrum Pharmaceuticals Inc., SymBio Pharmaceuticals Ltd., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., and TG Therapeutics Inc. among others. Furthremore, this diffuse large b-cell lymphoma (DLBCL) therapeutics market research report extensively covers diffuse large B-cell lymphoma (DLBCL) therapeutics market segmentation by product (small molecules and biologics) and geography (North America, Europe, Asia, and Rest of World (ROW)).

What will the Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market Size be During the Forecast Period?

Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market Size

Download the Free Report Sample to Unlock the Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market Size for the Forecast Period and Other Important Statistics

 

Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market: Key Drivers, Trends, and Challenges

The growing geriatric population is notably driving the diffuse large B-cell lymphoma (DLBCL) therapeutics market growth, although factors such as cytotoxicity of the drugs and inclination toward radiation treatments may impede market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the diffuse large B-cell lymphoma (DLBCL) therapeutics industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market Driver

 One of the key factors driving the global diffuse large b-cell lymphoma (DLBCL) therapeutics market growth is the growing geriatric population. According to the National Institutes of Health (NIH), the growth of the geriatric population is one of the factors leading to the increased prevalence of cancer. In addition, according to the CDC, in the US, the prevalence of cancer among people aged 40-44 years is about 9.3 per 100,000 people. With life expectancy rising, the proportion of individuals aged 60 years and above in 2020 was expected to be 11% globally, and by 2050, it is expected to rise up to 22%. Moreover, according to the US Census Bureau, by 2030, one out of every five residents in the US will be of retirement age. This is expected to contribute significantly to the growth of the market. Thus, the growth of the geriatric population will drive the growth of the global DLBCL therapeutics market during the forecast period.

Key Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market Trend

Technological advances is one of the key diffuse large B-cell lymphoma therapeutics market trends that is expected to impact the industry positively in the forecast period. Currently, many technological advances such as chimeric antigen receptor (CAR) T-cell therapy, gene therapy, companion diagnostics, and personalized medicines are being developed at a very rapid pace. For instance, recently launched Yescarta, a treatment for NHL by Gilead, is an example of CAR T-cell immune therapy. It is used when at least two other kinds of treatments are failed. In addition, Kymriah is the first-in-class CAR T therapy from Novartis for the treatment of patients with LBCL. Through such technological advances, industry-focused players such as Novartis and Gilead and diversified players such as F. Hoffmann-La Roche are focusing on CAR T-cell therapy and gene therapy. Such factors will further support the market growth in the coming years.

Key Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market Challenge

One of the key challenges to the global DLBCL market growth is the cytotoxicity of the drugs and inclination toward radiation treatments. Cytotoxicity not only affects the human cells but also affects the survival rates and quality of life of patients. All small molecules such as vincristine, doxorubicin, and carboplatin are cytotoxic to normal cells. Also, radiation therapy is the other option available for the treatment of NHL and DLBCL. It can be used as the primary treatment for some types of NHL if they are found early, as these tumors respond very well to radiation. Sometimes, radiation is used along with chemotherapy for the treatment of some lymphomas that are more aggressive. Thus, the side effects associated with chemotherapy drugs and radiation therapy are acting as a challenge for the market growth. 

This diffuse large b-cell lymphoma (DLBCL) therapeutics market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.

Who are the Major Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market Vendors?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

 

  • AbbVie Inc.
  • ADC Therapeutics SA
  • Amgen Inc.
  • Bayer AG
  • BeiGene Ltd.
  • Bristol Myers Squibb Co.
  • Celltrion Healthcare Co. Ltd.
  • CTI BioPharma Corp.
  • Denovo Biopharma
  • Erytech PharmaSA
  • F. Hoffmann La Roche Ltd.
  • Gilead Sciences Inc.
  • GlaxoSmithKline Plc
  • Merck and Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Seagen Inc.
  • Spectrum Pharmaceuticals Inc.
  • SymBio Pharmaceuticals Ltd.
  • Takeda Pharmaceutical Co. Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • TG Therapeutics Inc.

 

This statistical study of the diffuse large B-cell lymphoma (DLBCL) therapeutics market encompasses successful business strategies deployed by the key vendors. The diffuse large b-cell lymphoma (DLBCL) therapeutics market is fragmented and the vendors are deploying growth strategies such as investment in  R&D and technological innovation to compete in the market.

Product Insights and News

  • AbbVie Inc. - The company offers diffuse large B-cell lymphoma under the brand name Imbruvica.
  • AbbVie Inc. - Under this segment, the company conducts research and development, manufacturing, commercialization, and sale of innovative medicines and therapies to allocate resources and assess business performance on a global basis in order to achieve established long-term strategic goals.

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The diffuse large b-cell lymphoma (DLBCL) therapeutics market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Which are the Key Regions for Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market?

Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market Market segmentation by region

For more insights on the market share of various regions Request for a FREE sample now!

46% of the market's growth will originate from North America during the forecast period. US and Canada are the key markets for diffuse large b-cell lymphoma (DLBCL) therapeutics in North America. Market growth in this region will be faster than the growth of the market in Europe and ROW.

The significant increase in the sales of approved therapeutics for the treatment of various subtypes of NHL and the rise in prevalence of various cancer types, including DLBCL, will facilitate the diffuse large B-cell lymphoma (DLBCL) therapeutics market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

The outbreak of COVID-19 adversely affected all countries in North America, especially the US, in 2020. However, by the second half of 2021, lockdown-related restrictions were relaxed in various countries, which allowed the movement of people. Moreover, as pharmaceuticals were brought under essential services, the demand for and supply of DLBCL therapeutics was not affected much in North America. Like many other pharmaceutical products, DLBCL therapeutics were made available to the related stakeholders. Hence, the regional market will register growth during the forecast period.

What are the Revenue-generating Product Segments in the Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market?

Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market Segmentation

To gain further insights on the market contribution of various segments Request for a FREE sample

The diffuse large b-cell lymphoma (DLBCL) therapeutics market share growth by the small molecule segment will be significant during the forecast period. Small molecules are widely prescribed for the treatment of various types of lymphomas, including DLBCL, which can be life-threatening if left untreated. Thus, the global DLBCL therapeutics market by small molecules is expected to grow at a significant rate in the coming years. 

This report provides an accurate prediction of the contribution of all the segments to the growth of the diffuse large b-cell lymphoma (DLBCL) therapeutics market size and actionable market insights on post COVID-19 impact on each segment.

Parent Market Analysis

Technavio categorizes the global diffuse large b-cell lymphoma (DLBCL) market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the diffuse large b-cell lymphoma (DLBCL) therapeutics market during the forecast period.

Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the diffuse large b-cell lymphoma (DLBCL) therapeutics market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market Scope

Report Coverage

Details

Page number

120

Base year

2021

Forecast period

2022-2026

Growth momentum & CAGR

Accelerate at a CAGR of 7.71%

Market growth 2022-2026

$ 1.79 billion

Market structure

Fragmented

YoY growth (%)

6.9

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 46%

Key consumer countries

US, Canada, Germany, UK, and China

Competitive landscape

Leading companies, Competitive strategies, Consumer engagement scope

Key companies profiled

AbbVie Inc., ADC Therapeutics SA, Amgen Inc., Bayer AG, BeiGene Ltd., Bristol Myers Squibb Co., Celltrion Healthcare Co. Ltd., CTI BioPharma Corp., Denovo Biopharma, Erytech PharmaSA, F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Merck and Co. Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Seagen Inc., Spectrum Pharmaceuticals Inc., SymBio Pharmaceuticals Ltd., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., and TG Therapeutics Inc.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market Report?

  • CAGR of the market during the forecast period 2022-2026
  • Detailed information on factors that will drive diffuse large b-cell lymphoma (DLBCL) therapeutics market growth during the next five years
  • Precise estimation of the diffuse large b-cell lymphoma (DLBCL) therapeutics market size and its contribution to the parent market
  • Accurate predictions on upcoming trends and changes in consumer behavior
  • The growth of the diffuse large b-cell lymphoma (DLBCL) therapeutics industry across North America, Europe, Asia, and Rest of World (ROW)
  • A thorough analysis of the market's competitive landscape and detailed information on vendors
  • Comprehensive details of factors that will challenge the growth of diffuse large b-cell lymphoma (DLBCL) therapeutics market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Product
    • Exhibit 06: Executive Summary – Chart on Incremental Growth
    • Exhibit 07: Executive Summary – Data Table on Incremental Growth
    • Exhibit 08: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 09: Parent market
    • Exhibit 10: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 11: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 12: Market segments
  • 3.3 Market size 2021
    • 3.4 Market outlook: Forecast for 2021-2026
      • Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
      • Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
      • Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
      • Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

    4 Five Forces Analysis

    • 4.1 Five forces summary
      • Exhibit 17: Five forces analysis - Comparison between2021 and 2026
    • 4.2 Bargaining power of buyers
      • Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026
    • 4.3 Bargaining power of suppliers
      • Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026
    • 4.4 Threat of new entrants
      • Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026
    • 4.5 Threat of substitutes
      • Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026
    • 4.6 Threat of rivalry
      • Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026
    • 4.7 Market condition
      • Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

    5 Market Segmentation by Product

    • 5.1 Market segments
      • Exhibit 24: Chart on Product - Market share 2021-2026 (%)
      • Exhibit 25: Data Table on Product - Market share 2021-2026 (%)
    • 5.2 Comparison by Product
      • Exhibit 26: Chart on Comparison by Product
      • Exhibit 27: Data Table on Comparison by Product
    • 5.3 Small molecules - Market size and forecast 2021-2026
      • Exhibit 28: Chart on Small molecules - Market size and forecast 2021-2026 ($ million)
      • Exhibit 29: Data Table on Small molecules - Market size and forecast 2021-2026 ($ million)
      • Exhibit 30: Chart on Small molecules - Year-over-year growth 2021-2026 (%)
      • Exhibit 31: Data Table on Small molecules - Year-over-year growth 2021-2026 (%)
    • 5.4 Biologics - Market size and forecast 2021-2026
      • Exhibit 32: Chart on Biologics - Market size and forecast 2021-2026 ($ million)
      • Exhibit 33: Data Table on Biologics - Market size and forecast 2021-2026 ($ million)
      • Exhibit 34: Chart on Biologics - Year-over-year growth 2021-2026 (%)
      • Exhibit 35: Data Table on Biologics - Year-over-year growth 2021-2026 (%)
    • 5.5 Market opportunity by Product
      • Exhibit 36: Market opportunity by Product ($ million)

    6 Customer Landscape

    • 6.1 Customer landscape overview
      • Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    7 Geographic Landscape

    • 7.1 Geographic segmentation
      • Exhibit 38: Chart on Market share by geography 2021-2026 (%)
      • Exhibit 39: Data Table on Market share by geography 2021-2026 (%)
    • 7.2 Geographic comparison
      • Exhibit 40: Chart on Geographic comparison
      • Exhibit 41: Data Table on Geographic comparison
    • 7.3 North America - Market size and forecast 2021-2026
      • Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million)
      • Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million)
      • Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%)
      • Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%)
    • 7.4 Europe - Market size and forecast 2021-2026
      • Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million)
      • Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
      • Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%)
      • Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%)
    • 7.5 Asia - Market size and forecast 2021-2026
      • Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ million)
      • Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
      • Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%)
      • Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%)
    • 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
      • Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
      • Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
      • Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
      • Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
    • 7.7 US - Market size and forecast 2021-2026
      • Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million)
      • Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million)
      • Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%)
      • Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%)
    • 7.8 Germany - Market size and forecast 2021-2026
      • Exhibit 62: Chart on Germany - Market size and forecast 2021-2026 ($ million)
      • Exhibit 63: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
      • Exhibit 64: Chart on Germany - Year-over-year growth 2021-2026 (%)
      • Exhibit 65: Data Table on Germany - Year-over-year growth 2021-2026 (%)
    • 7.9 UK - Market size and forecast 2021-2026
      • Exhibit 66: Chart on UK - Market size and forecast 2021-2026 ($ million)
      • Exhibit 67: Data Table on UK - Market size and forecast 2021-2026 ($ million)
      • Exhibit 68: Chart on UK - Year-over-year growth 2021-2026 (%)
      • Exhibit 69: Data Table on UK - Year-over-year growth 2021-2026 (%)
    • 7.10 China - Market size and forecast 2021-2026
      • Exhibit 70: Chart on China - Market size and forecast 2021-2026 ($ million)
      • Exhibit 71: Data Table on China - Market size and forecast 2021-2026 ($ million)
      • Exhibit 72: Chart on China - Year-over-year growth 2021-2026 (%)
      • Exhibit 73: Data Table on China - Year-over-year growth 2021-2026 (%)
    • 7.11 Canada - Market size and forecast 2021-2026
      • Exhibit 74: Chart on Canada - Market size and forecast 2021-2026 ($ million)
      • Exhibit 75: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
      • Exhibit 76: Chart on Canada - Year-over-year growth 2021-2026 (%)
      • Exhibit 77: Data Table on Canada - Year-over-year growth 2021-2026 (%)
    • 7.12 Market opportunity by geography
      • Exhibit 78: Market opportunity by geography ($ million)

    8 Drivers, Challenges, and Trends

    • 8.1 Market drivers
      • 8.2 Market challenges
        • 8.3 Impact of drivers and challenges
          • Exhibit 79: Impact of drivers and challenges in 2021 and 2026
        • 8.4 Market trends

          9 Vendor Landscape

          • 9.1 Overview
            • 9.2 Vendor landscape
              • Exhibit 80: Overview on Criticality of inputs and Factors of differentiation
            • 9.3 Landscape disruption
              • Exhibit 81: Overview on factors of disruption
            • 9.4 Industry risks
              • Exhibit 82: Impact of key risks on business

            10 Vendor Analysis

            • 10.1 Vendors covered
              • Exhibit 83: Vendors covered
            • 10.2 Market positioning of vendors
              • Exhibit 84: Matrix on vendor position and classification
            • 10.3 AbbVie Inc.
              • Exhibit 85: AbbVie Inc. - Overview
              • Exhibit 86: AbbVie Inc. - Product / Service
              • Exhibit 87: AbbVie Inc. - Key offerings
            • 10.4 Amgen Inc.
              • Exhibit 88: Amgen Inc. - Overview
              • Exhibit 89: Amgen Inc. - Product / Service
              • Exhibit 90: Amgen Inc. - Key offerings
            • 10.5 Bayer AG
              • Exhibit 91: Bayer AG - Overview
              • Exhibit 92: Bayer AG - Business segments
              • Exhibit 93: Bayer AG - Key offerings
              • Exhibit 94: Bayer AG - Segment focus
            • 10.6 BeiGene Ltd.
              • Exhibit 95: BeiGene Ltd. - Overview
              • Exhibit 96: BeiGene Ltd. - Business segments
              • Exhibit 97: BeiGene Ltd. - Key offerings
              • Exhibit 98: BeiGene Ltd. - Segment focus
            • 10.7 Erytech PharmaSA
              • Exhibit 99: Erytech PharmaSA - Overview
              • Exhibit 100: Erytech PharmaSA - Product / Service
              • Exhibit 101: Erytech PharmaSA - Key offerings
            • 10.8 F. Hoffmann La Roche Ltd.
              • Exhibit 102: F. Hoffmann La Roche Ltd. - Overview
              • Exhibit 103: F. Hoffmann La Roche Ltd. - Business segments
              • Exhibit 104: F. Hoffmann La Roche Ltd. - Key news
              • Exhibit 105: F. Hoffmann La Roche Ltd. - Key offerings
              • Exhibit 106: F. Hoffmann La Roche Ltd. - Segment focus
            • 10.9 Merck and Co. Inc.
              • Exhibit 107: Merck and Co. Inc. - Overview
              • Exhibit 108: Merck and Co. Inc. - Business segments
              • Exhibit 109: Merck and Co. Inc. - Key news
              • Exhibit 110: Merck and Co. Inc. - Key offerings
              • Exhibit 111: Merck and Co. Inc. - Segment focus
            • 10.10 Novartis AG
              • Exhibit 112: Novartis AG - Overview
              • Exhibit 113: Novartis AG - Business segments
              • Exhibit 114: Novartis AG - Key offerings
              • Exhibit 115: Novartis AG - Segment focus
            • 10.11 Pfizer Inc.
              • Exhibit 116: Pfizer Inc. - Overview
              • Exhibit 117: Pfizer Inc. - Product / Service
              • Exhibit 118: Pfizer Inc. - Key news
              • Exhibit 119: Pfizer Inc. - Key offerings
            • 10.12 Spectrum Pharmaceuticals Inc.
              • Exhibit 120: Spectrum Pharmaceuticals Inc. - Overview
              • Exhibit 121: Spectrum Pharmaceuticals Inc. - Product / Service
              • Exhibit 122: Spectrum Pharmaceuticals Inc. - Key news
              • Exhibit 123: Spectrum Pharmaceuticals Inc. - Key offerings

            11 Appendix

            • 11.1 Scope of the report
              • 11.2 Inclusions and exclusions checklist
                • Exhibit 124: Inclusions checklist
                • Exhibit 125: Exclusions checklist
              • 11.3 Currency conversion rates for US$
                • Exhibit 126: Currency conversion rates for US$
              • 11.4 Research methodology
                • Exhibit 127: Research methodology
                • Exhibit 128: Validation techniques employed for market sizing
                • Exhibit 129: Information sources
              • 11.5 List of abbreviations
                • Exhibit 130: List of abbreviations

               

               

               

               

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              TechnavioINFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases
              Technavio

              TechnavioDATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts
              Technavio

              TechnavioREPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape
              Interested in this report?
              Get your sample now!
              Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market market growth will increase by $1.79 bn during 2022-2026.
              The diffuse large b-cell lymphoma (dlbcl) therapeutics market market is expected to grow at a CAGR of 7.71% during 2022-2026.
              Technavio has segmented the diffuse large b-cell lymphoma (dlbcl) therapeutics market market by product (Small molecules and Biologics) and geography (North America, Europe, Asia, and Rest of World (ROW)).
              AbbVie Inc., ADC Therapeutics SA, Amgen Inc., Bayer AG, BeiGene Ltd., Bristol Myers Squibb Co., Celltrion Healthcare Co. Ltd., CTI BioPharma Corp., Denovo Biopharma, Erytech PharmaSA, F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Merck and Co. Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Seagen Inc., Spectrum Pharmaceuticals Inc., SymBio Pharmaceuticals Ltd., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., TG Therapeutics Inc. are a few of the key vendors in the diffuse large b-cell lymphoma (dlbcl) therapeutics market market.
              North America will register the highest growth rate of 46% among the other regions. Therefore, the diffuse large b-cell lymphoma (dlbcl) therapeutics market market in North America is expected to garner significant business opportunities for the vendors during the forecast period.
              The key factors driving the diffuse large b-cell lymphoma (dlbcl) therapeutics market market growth are:
              • growing geriatric population
              • Technological advances
              The diffuse large b-cell lymphoma (dlbcl) therapeutics market market vendors should focus on grabbing business opportunities from the small molecules segment as it accounted for the largest market share in the base year.
              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?
              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis

              Certified ISO 9001 : 2015

              We are ISO recognized

              We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.

              We are GDPR and CCPA compliant

              We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.

              Safe and Secure SSL Encrypted
              Technavio

              info
              close
              • Single:

                One user only.
                Quick & easy download option

              • Enterprise:

                Unlimited user access (Within your organization)
                Complimentary Customization Included

              2500 USD

              Technavio Get the report (PDF) sent to your email within minutes.

              Subscribe & Save

              Get lifetime access to our
              Technavio Insights

              Customized Report as per your Business Needs

              • Our analysts will work directly with you and understand your needs
              • Get data on specified regions or segments, competitor and Vendors
              • Data will be formatted and presented as per your requirements
              • We offer $1000 worth of FREE customization at the time of purchase

              Let us help you make report more suited to your requirements.

              • Get a competitive breakdown as per your niche industry
              • Customize the data with various metrics that meet your business prerequisite
              • Understand Revenue Sources, Customers and many more
              • Details on Market Share
              • These customizations are done in a short amount of time by our analysts and industry experts
              Technavio
              Enquire Before Buying
              17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>